Clinical

Dataset Information

0

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)


ABSTRACT: Interventions: Arm A: FOLFIRI plus ramucirumab (Rmab) treatment - Rmab: 8 mg/kg/day1 - l-leucovorin (l-LV): 200 mg/m2/day1 - irinotecan (IRI): 180 mg/m2/day1 - bolus 5-FU: 400 mg/m2/day1 - infusional 5-FU: 2400 mg/m2/day1-3 Every 2 weeks Arm B: FOLFOXIRI plus Rmab treatment Induction therapy: 8 courses (maximum of 12 courses) - Rmab: 8 mg/kg/day1 - IRI: 165 mg/m2/day1 - l-LV: 200 mg/m2/day1 - oxaliplatin (OX): 85 mg/m2/day1 - infusional 5-FU: 3200 mg/m2/day1-3 Every 2 weeks Maintenance therapy: 5-FU/l-LV+Rmab, every 2 weeks Primary outcome(s): Objective response rate Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

DISEASE(S): First-line Treatment In Patients With Metastatic Colorectal Cancer

PROVIDER: 2614896 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2641746 | ecrin-mdr-crc
| 2622241 | ecrin-mdr-crc
| 2739106 | ecrin-mdr-crc
| 2617576 | ecrin-mdr-crc
| 2618714 | ecrin-mdr-crc
| 2625026 | ecrin-mdr-crc
| 2622791 | ecrin-mdr-crc
| 2614949 | ecrin-mdr-crc
| 2622610 | ecrin-mdr-crc
| 2643874 | ecrin-mdr-crc